Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NYSE
Oaktree Acquisition Corp II (OACB.U)
Oaktree Acquisition Corp II (OACB.U) Actualités

OACB.U

Oaktree Acquisition Corp... (OACB.U)

Oaktree Acquisition Corp II

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NYSE:OACB.U

1

Date	Heure	Source	Titre	Symbole	Société
24/05/2022	13h00	Business Wire	Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®	NYSE:OACB.U	Oaktree Acquisition Corp II
16/05/2022	14h00	Business Wire	Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®	NYSE:OACB.U	Oaktree Acquisition Corp II
20/04/2022	23h00	Business Wire	Alvotech améliore son accès aux capitaux et optimise son processus d’entrée en bourse, prévue sur le NASDAQ	NYSE:OACB.U	Oaktree Acquisition Corp II
20/04/2022	18h45	Business Wire	Alvotech verbessert Zugang zu Kapital und ebnet Weg für erwartete NASDAQ-Notierung	NYSE:OACB.U	Oaktree Acquisition Corp II
20/04/2022	14h15	Business Wire	Alvotech migliora l'accesso al capitale e semplifica il percorso verso la prevista quotazione in Borsa al NASDAQ	NYSE:OACB.U	Oaktree Acquisition Corp II
20/04/2022	00h00	Business Wire	Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange	NYSE:OACB.U	Oaktree Acquisition Corp II
08/04/2022	16h01	Business Wire	アルヴォテックとSTADA、アッヴィとの欧州特許紛争を解決してHumira®のクエン酸フリー高濃度バイオシミラーHUKYNDRA®（AVT02）発売への道を開く	NYSE:OACB.U	Oaktree Acquisition Corp II
07/04/2022	03h15	Business Wire	Alvotech et STADA ouvrent la voie au lancement de HUKYNDRA® (AVT02), un biosimilaire de l'Humira® haute concentration sans citrate, en réglant le litige de brevet européen qui les opposait à AbbVie	NYSE:OACB.U	Oaktree Acquisition Corp II
07/04/2022	00h21	Business Wire	Alvotech und STADA ebnen durch Beilegung des europäischen Patentstreits mit AbbVie den Weg für die Markteinführung von HUKYNDRA®(AVT02), einem zitratfreien, hochkonzentrierten Biosimilar zu Humira®	NYSE:OACB.U	Oaktree Acquisition Corp II
06/04/2022	13h00	Business Wire	Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie	NYSE:OACB.U	Oaktree Acquisition Corp II
09/12/2021	14h46	Business Wire	Alvotech et Oaktree Acquisition Corp. II annoncent un accord de fusion visant à créer une société biopharmaceutique internationale de premier plan cotée en Bourse	NYSE:OACB.U	Oaktree Acquisition Corp II
09/12/2021	07h34	Business Wire	Alvotech und Oaktree Acquisition Corp. II geben Fusionsvereinbarung zur Gründung eines führenden börsennotierten globalen Biopharmaunternehmens bekannt	NYSE:OACB.U	Oaktree Acquisition Corp II
07/12/2021	12h00	Business Wire	Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company	NYSE:OACB.U	Oaktree Acquisition Corp II
09/11/2020	15h16	Business Wire	Oaktree Acquisition Corp. II Announces the Separate Trading of its Class A Ordinary Shares & Warrants Commencing November 9, ...	NYSE:OACB.U	Oaktree Acquisition Corp II
21/09/2020	17h41	Business Wire	Oaktree Acquisition Corp. II Announces Closing of Initial Public Offering and Partial Exercise of Overallotment Option	NYSE:OACB.U	Oaktree Acquisition Corp II

Showing the most relevant articles for your search:NYSE:OACB.U

1

Porceleyne Fles

Reseau Ferre de France R...

Baltic International USA (PK)

SANTANDER BR PN

Greenwave Technology Sol...

B3 SA - Brasil Bolsa Bal... ON

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales